BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 22318401)

  • 1. Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer.
    Salvi S; Fontana V; Boccardo S; Merlo DF; Margallo E; Laurent S; Morabito A; Rijavec E; Dal Bello MG; Mora M; Ratto GB; Grossi F; Truini M; Pistillo MP
    Cancer Immunol Immunother; 2012 Sep; 61(9):1463-72. PubMed ID: 22318401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases.
    Paulsen EE; Kilvaer TK; Rakaee M; Richardsen E; Hald SM; Andersen S; Busund LT; Bremnes RM; Donnem T
    Cancer Immunol Immunother; 2017 Nov; 66(11):1449-1461. PubMed ID: 28707078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of PDCD1 and CTLA-4 Gene Expression with Clinicopathological Factors and Survival in Non-Small-Cell Lung Cancer: Results from a Large and Pooled Microarray Database.
    Deng L; Gyorffy B; Na F; Chen B; Lan J; Xue J; Zhou L; Lu Y
    J Thorac Oncol; 2015 Jul; 10(7):1020-6. PubMed ID: 26134222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
    Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM
    Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors.
    Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Di Carlo L; Semeraro A; Daddi G; Darwish S; Stocchi L; Tofanetti FR; Bellezza G; Sidoni A; Tognellini R; Crinò L; Tonato M
    Tumori; 2008; 94(3):398-405. PubMed ID: 18705409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CTLA-4 +49A>G polymorphism is associated with advanced non-small cell lung cancer prognosis.
    Song B; Liu Y; Liu J; Song X; Wang Z; Wang M; Zhu Y; Han J
    Respiration; 2011; 82(5):439-44. PubMed ID: 21832820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment.
    Song L; Wang X; Cheng W; Wu Y; Liu M; Liu R; Zhang S; Xia H; Liu H; Tai X; Zhao H; Li X; Ji F
    BMC Pulm Med; 2021 Dec; 21(1):420. PubMed ID: 34923982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ctla-4 expression and polymorphisms in lung tissue of patients with diagnosed non-small-cell lung cancer.
    Antczak A; Pastuszak-Lewandoska D; Górski P; Domańska D; Migdalska-Sęk M; Czarnecka K; Nawrot E; Kordiak J; Brzeziańska E
    Biomed Res Int; 2013; 2013():576486. PubMed ID: 23936819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC).
    Erfani N; Mehrabadi SM; Ghayumi MA; Haghshenas MR; Mojtahedi Z; Ghaderi A; Amani D
    Lung Cancer; 2012 Aug; 77(2):306-11. PubMed ID: 22608141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
    Tan Q; Li H; Yu M; Tang X; Tan J; Zhang S; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):254-264. PubMed ID: 33910273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
    Li B; Cui Y; Diehn M; Li R
    JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CTLA-4, CD28, and ICOS gene polymorphism associations with non-small-cell lung cancer.
    Karabon L; Pawlak E; Tomkiewicz A; Jedynak A; Passowicz-Muszynska E; Zajda K; Jonkisz A; Jankowska R; Krzakowski M; Frydecka I
    Hum Immunol; 2011 Oct; 72(10):947-54. PubMed ID: 21669243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer.
    O'Callaghan DS; Rexhepaj E; Gately K; Coate L; Delaney D; O'Donnell DM; Kay E; O'Connell F; Gallagher WM; O'Byrne KJ
    Eur Respir J; 2015 Dec; 46(6):1762-72. PubMed ID: 26541534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I non-small cell lung cancer.
    Mitchell KG; Parra ER; Nelson DB; Zhang J; Wistuba II; Fujimoto J; Roth JA; Antonoff MB;
    J Thorac Cardiovasc Surg; 2019 Sep; 158(3):911-919.e6. PubMed ID: 31235357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer.
    Soo RA; Kim HR; Asuncion BR; Fazreen Z; Omar MFM; Herrera MC; Yun Lim JS; Sia G; Soong R; Cho BC
    Lung Cancer; 2017 Mar; 105():17-22. PubMed ID: 28236980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis.
    Pelletier MP; Edwardes MD; Michel RP; Halwani F; Morin JE
    Can J Surg; 2001 Jun; 44(3):180-8. PubMed ID: 11407827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy.
    Li C; Pan J; Luo J; Chen X
    BMC Pulm Med; 2021 Nov; 21(1):389. PubMed ID: 34844602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. Impact on long-term survival.
    Selvaggi G; Scagliotti GV; Torri V; Novello S; Leonardo E; Cappia S; Mossetti C; Ardissone F; Lausi P; Borasio P
    Cancer; 2002 May; 94(10):2669-74. PubMed ID: 12173335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
    Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L
    Front Immunol; 2021; 12():731546. PubMed ID: 34484242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
    Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
    Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.